ATS (ATS) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
19 May, 2026Opening remarks and agenda
Meeting opened with a welcome, introduction of board and executive team, and emphasis on shareholder engagement.
Agenda included business updates, financial review, election of directors, auditor reappointment, and executive compensation advisory vote.
Financial performance review
Fiscal 2024 delivered record revenues of CAD 3 billion and adjusted earnings of CAD 398 million, with 18% revenue growth and 11% organic growth.
Order bookings reached CAD 2.9 billion, ending with a CAD 1.8 billion backlog; adjusted EBITDA margin was 15.5%.
Five-year compound annual revenue growth averaged 19.3%, with adjusted EBITDA growing 23.7% annually.
Cash from operations was CAD 21 million, with a free cash outflow of CAD 68 million; net debt to adjusted EBITDA at 2.4:1.
Board and executive committee updates
Board advanced ESG priorities, supported capital allocation strategies, and oversaw four acquisitions enhancing services, digitization, and AI capabilities.
Sustainability committee is now fully active, alongside Audit, Governance, HR, and Strategic Opportunities committees.
Latest events from ATS
- C$3.0B adjusted revenue, strong M&A, and disciplined growth in automation markets.ATS
Investor presentation29 May 2026 - Revenue and earnings rose in fiscal 2026, with restructuring driving margin expansion.ATS
Q4 202628 May 2026 - Flexible shelf offering supports growth in automation for regulated, high-value markets.ATS
Registration filing27 Apr 2026 - C$2.9B adjusted revenues, 13.8% EBITDA margin, and robust M&A fuel global automation growth.ATS
Investor presentation19 Apr 2026 - Margin expansion, portfolio diversification, and disciplined M&A drive future growth plans.ATS
47th Annual Raymond James Institutional Investor Conference3 Mar 2026 - Q3 revenue up 16.7%, net income surges, and strong backlog supports future growth.ATS
Q3 20264 Feb 2026 - Life sciences and nuclear energy drive growth, with disciplined M&A and resilient market focus.ATS
Raymond James 46th Annual Institutional Investors Conference3 Feb 2026 - Order bookings surged 18.4% as life sciences growth offset transportation softness.ATS
Q1 20252 Feb 2026 - Tripled revenue, tech innovation, and services expansion drive growth in life sciences and EV.ATS
Stifel 2024 Cross Sector Insight Conference31 Jan 2026